At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
01801 INNOVENT BIO
Not Yet Opened 09-16 16:08:16
44.200
+0.150
+0.34%
High44.500
Low42.550
Vol2.66M
Open44.000
D1 Closing44.050
Amplitude4.43%
Mkt Cap72.01B
Tradable Cap72.01B
Total Shares1.63B
T/O116.59M
T/O Rate0.16%
Tradable Shares1.63B
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
China Galaxy Securities Starts Innovent Biologics at Add with HK$55.92 Price Target
Head-to-Head Superiority Over Dulaglutide: Innovent's Phase 3 Clinical Trial Dreams-2 of Mazdutide in Chinese Patients With Type 2 Diabetes Were Orally Presented at Easd 2024
Innovent Receives Fast Track Designation From the U.S. FDA for Ibi363 (Pd-1/Il-2Α Bispecific Antibody Fusion Protein) as Monotherapy for Advanced Melanoma
Innovent Biologics Inc is an investment holding company principally engaged in biopharmaceuticals. The Company and its subsidiaries are engaged in research and development of antibody and protein medicine products, sale and distribution of pharmaceutical products, and provision of consultation and research and development services. The Company's main product is Tyvyt (sintilimab injection), which is used to treat relapsed or refractory classical Hodgkin’s lymphoma. The Company's products also include adalimumab biosimilar IBI-303, which is used to treat rheumatoid arthritis, ankylosing spondylitis and psoriasis. Bevacizumab biosimilar IBI-305 is used to treat metastatic colorectal cancer and advanced, metastatic or recurrent non-small-cell lung cancer (NSCLC). Rituximab biosimilar IBI-301 is used to treat non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Its products are used in oncology, metabolic, immunology and ophthalmology diseases.